<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127452</url>
  </required_header>
  <id_info>
    <org_study_id>METC-ZWH 0552</org_study_id>
    <secondary_id>NHF-2000T401</secondary_id>
    <secondary_id>L01.049</secondary_id>
    <secondary_id>5R01HL076200</secondary_id>
    <nct_id>NCT00127452</nct_id>
    <nct_alias>NCT00139464</nct_alias>
  </id_info>
  <brief_title>Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality</brief_title>
  <official_title>Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alpha Omega Trial is a randomized, placebo-controlled, double-blind dietary intervention
      study in 4837 postmyocardial infarction patients in the Netherlands to examine whether
      incidence of cardiovascular diseases during 40 months of follow-up can be prevented by low
      doses of omega-3 polyunsaturated fatty acids. The key objectives are:

        -  to examine the effect of low-dose supplementation (400 mg/day) of eicosapentaenoic acid
           and docosahexaenoic acid on incidence of cardiovascular diseases; and

        -  to examine the effect of low-dose supplementation (2 g/day) of alpha-linolenic acid on
           incidence of cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whether dietary omega-3 (or n-3) polyunsaturated fatty acids are causally related to risk of
      cardiovascular diseases (CVD) is a major, unresolved question in preventive cardiology.
      Essential n-3 fatty acids are eicosapentaenoic acid (EPA; C20:5, n-3) and docosahexaenoic
      acid (DHA; C22:6, n-3) on one hand, and their parent compound alpha-linolenic acid (ALA;
      C18:3, n-3) on the other hand. The intake of n-3 fatty acids is below recommended levels in
      most Western populations. The Alpha Omega Trial is a randomized, double-blind,
      placebo-controlled study of the effect of low-dose supplementation of ALA and EPA-DHA on CVD.
      A total of 4837 Dutch men and women aged 60-80 years who had a myocardial infarction in the
      past 10 years are randomly allocated to 2 g/d of ALA, 400 mg/d of EPA-DHA, 2 g/d ALA + 400
      mg/d EPA-DHA, or placebo, for 40 months. Increased intake of n-3 fatty acids is achieved
      through daily use of 20 g of margarine on bread. Margarines for all treatment groups are
      similar in taste and appearance. The primary outcome of the trial is 'major cardiovascular
      events', which comprises incident CVD and cardiac interventions (PCI and CABG) during
      follow-up. Secondary endpoints are incident CVD, fatal CVD, fatal CHD and all-causes
      mortality. Complete follow-up for vital status is achieved. Cause-specific mortality is coded
      by an independent Endpoint Adjudication Committee. Physical examination, blood sampling and
      data collection on diet and lifestyle are performed in all subjects at baseline, in 810
      randomly selected subjects after 20 months of intervention, and in 58% of the cohort at the
      end of follow-up. Cardiovascular health, serious adverse events, lifestyle, fish intake and
      margarine use are monitored in all subjects by yearly telephone interviews. Compliance is
      continuously monitored by registration of margarine tubs. An objective biomarker of
      compliance (i.e. plasma n-3 fatty acids) is obtained in randomly selected subjects at
      baseline and after 20 and 40 months of intervention. The Alpha Omega Trial could provide a
      sound scientific basis for dietary recommendations on intake of ALA and EPA-DHA, in order to
      reduce the burden of cardiovascular diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular events, which comprises fatal cardiovascular diseases (CVD), non-fatal myocardial infarction, non-fatal cardiac arrest, non-fatal stroke and cardiac interventions (PCI and CABG)</measure>
    <time_frame>monitored during intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident CVD, which comprises fatal CVD, non-fatal myocardial infarction, non-fatal cardiac arrest and non-fatal stroke</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal CVD, which comprises mortality from ischaemic heart disease, fatal cardiac arrest, sudden death undefined, mortality from heart failure and fatal stroke</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal CHD, which comprises mortality from ischaemic heart disease, mortality from cardiac arrest, and sudden death undefined</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-causes mortality</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of sudden death undefined and nonfatal and fatal cardiac arrest</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of sudden death undefined, nonfatal and fatal cardiac arrest, and self-reported placement of any implantable cardioverter-defibrillator, verified in medical records</measure>
    <time_frame>monitored during intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4837</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>EPA + DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA + DHA plus ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>margarine spread</intervention_name>
    <description>Daily use of margarine spread (approximately 20 grams) during 40 months</description>
    <arm_group_label>EPA + DHA</arm_group_label>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_label>EPA + DHA plus ALA</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men and women

          -  Aged 60 through 80 y

          -  Verified clinically diagnosed myocardial infarction up to 10 y before randomization

          -  Written informed consent

        Exclusion criteria:

          -  Living in a nursing home or other institution

          -  Participation in another scientific study

          -  Habitual margarine intake &lt; 10 g per day

          -  Habitual fish intake &gt; 150 g per day

          -  Habitual alcohol intake &gt; 6 drinks per day

          -  Use of fish oil capsules or other supplements containing omega-3 fatty acids

          -  Presence of cancer with &lt; 1 y of life expectancy

          -  Cognitive impairment, as indicated by the Mini Mental State Examination (score &lt;= 21)

          -  Unintended weight loss &gt; 5 kg in the past year

          -  Lack of facilities for cooled margarine storage at home

          -  Inability or unwillingness to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daan Kromhout, PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevo Ziekenhuis</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3800 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1006 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BovenIJ Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1034 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaartziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lievensberg Ziekenhuis</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4600 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940 EB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis</name>
      <address>
        <city>Capelle aan den IJssel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Ziekenhuis</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oosterscheldeziekenhuis</name>
      <address>
        <city>Goes</city>
        <zip>4462 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Hilversum</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnland Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Havenziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis, location Leyweg</name>
      <address>
        <city>The Hague</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronovo Ziekenhuis</name>
      <address>
        <city>The Hague</city>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis, location Sportlaan</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twee Steden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alysis Ziekenhuis</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <zip>6700 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'t Lange Land ziekenhuis</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.alphaomegatrial.com</url>
    <description>Information site of the Alpha Omega Trial; statistical analysis plans are posted here</description>
  </link>
  <link>
    <url>http://www.wur.nl</url>
    <description>Wageningen University and Research Centre</description>
  </link>
  <link>
    <url>http://www.humannutrition.wur.nl</url>
    <description>Division of Human Nutrition, Wageningen University, The Netherlands</description>
  </link>
  <link>
    <url>http://www.vlaggraduateschool.nl/</url>
    <description>The Graduate School VLAG, Wageningen, The Netherlands</description>
  </link>
  <link>
    <url>http://www.hartstichting.nl</url>
    <description>Netherlands Heart Foundation</description>
  </link>
  <reference>
    <citation>Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D; Alpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010 Apr;159(4):539-546.e2. doi: 10.1016/j.ahj.2009.12.033.</citation>
    <PMID>20362710</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daan Kromhout</name_title>
    <organization>Wageningen University</organization>
  </responsible_party>
  <keyword>alpha-linolenic acid</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>coronary patients</keyword>
  <keyword>DHA</keyword>
  <keyword>dietary intervention</keyword>
  <keyword>dietary supplementation</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>EPA</keyword>
  <keyword>fish oil</keyword>
  <keyword>fish fatty acids</keyword>
  <keyword>human subjects</keyword>
  <keyword>ischaemic heart disease</keyword>
  <keyword>margarine</keyword>
  <keyword>marine fatty acids</keyword>
  <keyword>mortality</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>n-3 fatty acids</keyword>
  <keyword>n-3 polyunsaturated fatty acids</keyword>
  <keyword>n-3 PUFA</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>omega-3 polyunsaturated fatty acids</keyword>
  <keyword>prevention</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>secondary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

